Key Golimumab Trials in Ulcerative Colitis


Click here to browse all videos in this series

This Elsevier video reprint highlights William J. Sandborn, MD, and his review of the clinical trials Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-To-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis, as published in Gastroenterology in 2014.1-2

Dr. Sandborn is Chief of the Division of Gastroenterology and Professor of Medicine at the University of California at San Diego School of Medicine. He has received consulting fees from or performed contracted research for Janssen, Abbvie, UCB Pharma, Takeda, Pfizer, Amgen, Genentech, Receptos, Actavis, Shire, Salix, Prometheus Laboratories in the past 12 months.